Journal of Medicinal Chemistry · 2011 · 44 citations · 51 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryNeuropharmacologyStructure-activity RelationshipsLead Compound DesignLigand BindingReceptor ModelingReceptor PharmacologySerotonergic PharmacologyStructure-activity Relationship Analysis5-Hydroxytryptamine 1A Receptor Agonists5-Hydroxytryptamine Receptor PharmacologyAgonist ActivityBinding Affinity AssessmentCerebral Ischemia NeuroprotectionSerotonergic Drug DiscoverySerotonin AgonistsSerotonin Receptor Pharmacology
We report the synthesis of new compounds 4-35 based on structural modifications of different moieties of previously described lead UCM-2550. The new nonpiperazine derivatives, representing second-generation agonists, were assessed for binding affinity, selectivity, and functional activity at the 5-HT(1A) receptor (5-HT(1A)R). Computational β(2)-based homology models of the ligand-receptor complexes were used to explain the observed structure-affinity relationships. Selected candidates were also evaluated for their potential in vitro and in vivo neuroprotective properties. Interestingly, compound 26 (2-{6-[(3,4-dihydro-2H-chromen-2-ylmethyl)amino]hexyl}tetrahydro-1H-pyrrolo[1,2-c]imidazole-1,3(2H)-dione) has been characterized as a high-affinity and potent 5-HT(1A)R agonist (K(i) = 5.9 nM, EC(50) = 21.8 nM) and exhibits neuroprotective effect in neurotoxicity assays in primary cell cultures from rat hippocampus and in the MCAO model of focal cerebral ischemia in rats.
51
Structure of a nanobody-stabilized active state of the β2 adrenoceptor
Søren G. F. Rasmussen, Hee‐Jung Choi, Juan José Fung et al. · Nature · 2011 · 1.7K citations · Full text
Structure of a β1-adrenergic G-protein-coupled receptor
Tony Warne, María J. Serrano‐Vega, Jillian G. Baker et al. · Nature · 2008 · 1.3K citations · Full text